- cafead Mar 04, 2020 at 11:12: AM
via Before, doctors believed Novartis’ new option offered better efficacy and an improved dosing schedule versus Regeneron’s Eylea, Raymond wrote.
“Then lightning struck,” he added. “The world changed with the ASRS communication regarding cases of occlusive vasculitis in Beovu treated patients.”
article source
“Then lightning struck,” he added. “The world changed with the ASRS communication regarding cases of occlusive vasculitis in Beovu treated patients.”
article source